Trial Profile
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary) ; Vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 27 Jun 2018 Results of a pooled post-hoc analysis from ten studies published in the Drugs and Aging.
- 23 May 2018 Results of a post-hoc analysis from NCT01316900, NCT01313650, NCT01316913, NCT01817764, NCT01879410, NCT02152605, and NCT01777334 studies presented at the 114th International Conference of the American Thoracic Society.
- 23 May 2018 Results of pooled, post hoc intention-to-treat analysis assessing the impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease using data from two large 6-month placebo-controlled trials (NCT01313637 [n=1489], NCT01313650 [n=1532]), presented at the 114th International Conference of the American Thoracic Society.